These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Inhibition of IK,ACh current may contribute to clinical efficacy of class I and class III antiarrhythmic drugs in patients with atrial fibrillation. Voigt N, Rozmaritsa N, Trausch A, Zimniak T, Christ T, Wettwer E, Matschke K, Dobrev D, Ravens U. Naunyn Schmiedebergs Arch Pharmacol; 2010 Mar; 381(3):251-9. PubMed ID: 19760273 [Abstract] [Full Text] [Related]
5. Analysis of electropharmacological effects of AVE0118 on the atria of chronic atrioventricular block dogs: characterization of anti-atrial fibrillatory action by atrial repolarization-delaying agent. Kambayashi R, Hagiwara-Nagasawa M, Ichikawa T, Goto A, Chiba K, Nunoi Y, Izumi-Nakaseko H, Matsumoto A, Takahara A, Sugiyama A. Heart Vessels; 2020 Sep; 35(9):1316-1322. PubMed ID: 32346771 [Abstract] [Full Text] [Related]
8. Ionic targets for drug therapy and atrial fibrillation-induced electrical remodeling: insights from a mathematical model. Courtemanche M, Ramirez RJ, Nattel S. Cardiovasc Res; 1999 May; 42(2):477-89. PubMed ID: 10533583 [Abstract] [Full Text] [Related]
9. The new antiarrhythmic drug vernakalant: ex vivo study of human atrial tissue from sinus rhythm and chronic atrial fibrillation. Wettwer E, Christ T, Endig S, Rozmaritsa N, Matschke K, Lynch JJ, Pourrier M, Gibson JK, Fedida D, Knaut M, Ravens U. Cardiovasc Res; 2013 Apr 01; 98(1):145-54. PubMed ID: 23341576 [Abstract] [Full Text] [Related]
12. Impaired Na⁺-dependent regulation of acetylcholine-activated inward-rectifier K⁺ current modulates action potential rate dependence in patients with chronic atrial fibrillation. Voigt N, Heijman J, Trausch A, Mintert-Jancke E, Pott L, Ravens U, Dobrev D. J Mol Cell Cardiol; 2013 Aug 01; 61():142-52. PubMed ID: 23531443 [Abstract] [Full Text] [Related]
16. Blockade of atrial-specific K+-currents increases atrial but not ventricular contractility by enhancing reverse mode Na+/Ca2+-exchange. Schotten U, de Haan S, Verheule S, Harks EG, Frechen D, Bodewig E, Greiser M, Ram R, Maessen J, Kelm M, Allessie M, Van Wagoner DR. Cardiovasc Res; 2007 Jan 01; 73(1):37-47. PubMed ID: 17157284 [Abstract] [Full Text] [Related]
17. Role of IKur in controlling action potential shape and contractility in the human atrium: influence of chronic atrial fibrillation. Wettwer E, Hála O, Christ T, Heubach JF, Dobrev D, Knaut M, Varró A, Ravens U. Circulation; 2004 Oct 19; 110(16):2299-306. PubMed ID: 15477405 [Abstract] [Full Text] [Related]
18. The G protein-gated potassium current I(K,ACh) is constitutively active in patients with chronic atrial fibrillation. Dobrev D, Friedrich A, Voigt N, Jost N, Wettwer E, Christ T, Knaut M, Ravens U. Circulation; 2005 Dec 13; 112(24):3697-706. PubMed ID: 16330682 [Abstract] [Full Text] [Related]
19. Raloxifene inhibits transient outward and ultra-rapid delayed rectifier potassium currents in human atrial myocytes. Liu H, Jin MW, Xiang JZ, Huang Y, Sun HY, Chiu SW, Lau CP, Li GR. Eur J Pharmacol; 2007 Jun 01; 563(1-3):61-8. PubMed ID: 17337266 [Abstract] [Full Text] [Related]